The response of mouse pancreas to gradient cholecystokinin

doi:10.11958/20220309

Abstract

Abstract:

Objective To investigate the effect of cholecystokinin (CCK) on pancreas and occurrence of pancreatic cancer, and to explore the anticancer effect of a component of green tea, epigallocatechin galate (EGCG). Methods Growing mice were randomly divided into 4 groups, and mice were given water containing soybean trypsin inhibitor (STI) 0 g/L (n=11), 2 g/L (n=11), 4 g/L (n=10) and 8 g/L (n=11), respectively. After 2 weeks, mice were sacrificed and the wet weight of pancreas was recorded. Plasma CCK level was detected by enzyme-linked immunosorbent assay (ELISA). The contents of protein, DNA, trypsin and lipase in pancreatic tissue were determined. The percentage of proliferating cell nuclear antigen (PCNA) positive cells in pancreatic tissue was detected by immunohistochemical staining. The carcinogenesis model was established by embedding dimethyl benzoanthracene (DMBA) in pancreas. Fifteen mice were randomly divided into the normal control group, the DMBA embedding group, the DMBA+2 g/L STI group, the DMBA+8 g/L STI group and the DMBA+8 g/L STI+EGCG group. After 6 weeks, the mice were sacrificed and the pancreas was taken for histological analysis. Results CCK level was higher in the 2 g/L STI group than that in the 0 g/L STI group, and which was higher in the 8 g/L STI group than that in the 0, 2 and 4 g/L STI group (P<0.05). The wet weight of pancreas was higher in the 2 g/L STI group and the 4 g/L STI group than that in the 0 g/L STI group, and which was higher in the 8 g/L STI group than that in the 0 g/L STI group and the 2 g/L STI group (P<0.05). The contents of pancreatic protein and DNA were higher in the 2 g/L STI group and 4 g/L STI group than those in the 0 g/L STI group, and which were higher in the 8 g/L STI group than those in the 0 g/L STI group, 2 g/L STI group and 4 g/L STI group (P<0.05). The content of trypsin increased successively in the 0 g/L STI group, the 2 g/L STI group, the 4 g/L STI group and the 8 g/L STI group. The lipase content was significantly higher in the 2 g/L STI group, the 4 g/L STI group and the 8 g/L STI group than that in the 0 g/L STI group (P < 0.05). The proportion of PCNA-positive cells in pancreatic tissue of mice increased successively in the 0 g/L STI group, 2 g/L STI group, the 4 g/L STI group and the 8 g/L STI group (P < 0.05). The degree of pancreatic cancer prelesion was aggravated with the increase of STI dose in drinking water, and EGCG can alleviate this lesion. Conclusion STI can induce gradient cholecystokininemia, stimulate pancreatic hyperplasia, trypsin production and pancreatic cancer, while EGCG can alleviate pancreatic precancerous lesions.

Key words: Soybean trypsin inhibitor, cholecystokinin, pancreatic growth, trypsin, lipase, Epigallocatechin gallate

CLC Number:

R335.9

Figures/Tables 5

References 12

[1]	REHFELD JF. Cholecystokinin and the hormone concept[J]. Endocr Connect, 2021, 10(3):R139-R150. doi: 10.1530/EC-21-0025.
[2]	MARTIN A M, SUN E W, KEATING D J. Mechanisms controlling hormone secretion in human gut and its relevance to metabolism[J]. J Endocrinol, 2019, 244(1):R1-R15. doi: 10.1530/JOE-19-0399.
[3]	NAKAJIMA S, HIRA T, TSUBATA M, et al. Potato extract (Potein) suppresses food intake in rats through inhibition of luminal trypsin activity and direct stimulation of cholecystokinin secretion from enteroendocrine cells[J]. J Agric Food Chem, 2011, 59(17):9491-9496. doi: 10.1021/jf200988f.
[4]	WEN S, LI Z, FENG J, et al. Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats[J]. Cancer Sci, 2016, 107(6):836-845. doi: 10.1111/cas.12939.
[5]	ALMATROODI S A, ALMATROUDI A, KHAN A A, et al. Potential therapeutic targets of Epigallocatechin Gallate (EGCG),the most abundant catechin in green tea,and its role in the therapy of various types of cancer[J]. Molecules, 2020, 25(14):3146. doi: 10.3390/molecules25143146.
[6]	AGAWA S, FUTAGAMI S, YAMAWAKI H, et al. State of anxiety may be associated with exocrine pancreatic insufficiency in functional dyspepsia patients with pancreatic enzyme abnormalities[J]. J Clin Biochem Nutr, 2022, 70(2):175-181. doi: 10.3164/jcbn.21-67.
[7]	CHEN X, QIU S, LI Q, et al. Pancreatobiliary diversion in the mouse[J]. Eur Surg Res, 2020, 61(4/5):130-135. doi: 10.1159/000508270.
[8]	HUANG J, LOK V, NGAI C H, et al. Worldwide burden of,risk factors for,and trends in pancreatic cancer[J]. Gastroenterology, 2021, 160(3):744-754. doi: 10.1053/j.gastro.2020.10.007.
[9]	POURSHAMS A, SEPANLOU S G, IKUTA K S, et al. The global,regional,and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2019, 4(12):934-947. doi: 10.1016/S2468-1253(19)30347-4.
[10]	ADHAMI V M, MALIK A, ZAMAN N, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo[J]. Clin Cancer Res, 2007, 13(5):1611-1619. doi: 10.1158/1078-0432.CCR-06-2269.
[11]	LAW N C, WHITE M F, HUNZICKER-DUNN M E. G protein-coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway[J]. J Biol Chem, 2016, 291(53):27160-27169. doi: 10.1074/jbc.M116.763235.
[12]	HU L, CHEN X, QIU S, et al. Intra-pancreatic insulin nourishes cancer cells:do insulin-receptor antagonists such as PGG and EGCG play a role[J]. Am J Chin Med, 2020, 48(4):1005-1019. doi: 10.1142/S0192415X20500482.

组别	n	CCK（ng/L）	胰腺湿质量（mg）
0 g/L STI组	11	57.33±15.23	152.64±17.74
2 g/L STI组	11	79.08±13.13^a	185.73±31.92^a
4 g/L STI组	10	67.06±9.62	198.80±29.02^a
8 g/L STI组	11	92.84±9.25^abc	220.45±43.66^ab
F		17.512^＊＊	8.619^＊＊

组别	n	CCK（ng/L）	胰腺湿质量（mg）
0 g/L STI组	11	57.33±15.23	152.64±17.74
2 g/L STI组	11	79.08±13.13^a	185.73±31.92^a
4 g/L STI组	10	67.06±9.62	198.80±29.02^a
8 g/L STI组	11	92.84±9.25^abc	220.45±43.66^ab
F		17.512^＊＊	8.619^＊＊

组别	n	蛋白质含量（mg）	DNA含量（μg）
0 g/L STI组	11	14.30±2.37	228.29±27.03
2 g/L STI组	11	19.70±4.72^a	281.87±35.36^a
4 g/L STI组	10	20.63±4.49^a	299.26±34.12^a
8 g/L STI组	11	25.85±5.68^abc	346.62±32.88^abc
F		12.252^＊＊	24.892^＊＊

组别	n	蛋白质含量（mg）	DNA含量（μg）
0 g/L STI组	11	14.30±2.37	228.29±27.03
2 g/L STI组	11	19.70±4.72^a	281.87±35.36^a
4 g/L STI组	10	20.63±4.49^a	299.26±34.12^a
8 g/L STI组	11	25.85±5.68^abc	346.62±32.88^abc
F		12.252^＊＊	24.892^＊＊

组别	n	胰蛋白酶含量（U/mg）	胰脂酶含量（ng/g）
0 g/L STI组	11	5.53±0.62	325.89±63.38
2 g/L STI组	11	6.86±0.57^a	435.03±35.89^a
4 g/L STI组	10	7.98±0.57^ab	468.73±82.43^a
8 g/L STI组	11	9.74±0.88^abc	469.35±96.56^a
F		76.520^＊＊	9.391^＊＊